Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis

Simple item page
dc.contributor.authorTait, D. R.en_ZA
dc.contributor.authorHatherill, M.en_ZA
dc.contributor.authorVan Der Meeren, O.en_ZA
dc.contributor.authorGinsberg, A. M.en_ZA
dc.contributor.authorVan Brakel, E.en_ZA
dc.contributor.authorSalaun, B.en_ZA
dc.contributor.authorScriba, T. J.en_ZA
dc.contributor.authorAkite, E. J.en_ZA
dc.contributor.authorAyles, H. M.en_ZA
dc.contributor.authorBollaerts, A.en_ZA
dc.contributor.authorDemoitie, M. -A.en_ZA
dc.contributor.authorDiacon, A.en_ZA
dc.contributor.authorEvans, T. G.en_ZA
dc.contributor.authorGillard, P.en_ZA
dc.contributor.authorHellstrom, E.en_ZA
dc.contributor.authorInnes, J. C.en_ZA
dc.contributor.authorLempicki, M.en_ZA
dc.contributor.authorMalahleha, M.en_ZA
dc.contributor.authorMartinson, N.en_ZA
dc.contributor.authorVela, D. Mesiaen_ZA
dc.contributor.authorMuyoyeta, M.en_ZA
dc.contributor.authorNduba, V.en_ZA
dc.contributor.authorPascal, T. G.en_ZA
dc.contributor.authorTameris, M.en_ZA
dc.contributor.authorThienemann, F.en_ZA
dc.contributor.authorWilkinson, R. J.en_ZA
dc.contributor.authorRoman, F.en_ZA
dc.date.accessioned2021-10-18T10:00:28Zen_ZA
dc.date.available2021-10-18T10:00:28Zen_ZA
dc.date.issued2019-12-19en_ZA
dc.descriptionCITATION: Tait, Dereck R. et al. 2019. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 381(25):2429-2439. doi:10.1056/NEJMoa1909953en_ZA
dc.descriptionThe original publication is available at https://www.nejm.org/en_ZA
dc.description.abstractBACKGROUND: Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity. METHODS: From August 2014 through November 2015, we enrolled adults 18 to 50 years of age with M. tuberculosis infection (defined by positive results on interferon-γ release assay) without evidence of active tuberculosis disease at centers in Kenya, South Africa, and Zambia. Participants were randomly assigned in a 1:1 ratio to receive two doses of either M72/AS01E or placebo, administered 1 month apart. The primary objective was to evaluate the efficacy of M72/AS01E to prevent active pulmonary tuberculosis disease according to the first case definition (bacteriologically confirmed pulmonary tuberculosis not associated with human immunodeficiency virus infection). Participants were followed for 3 years after the second dose. Participants with clinical suspicion of tuberculosis provided sputum samples for polymerase-chain-reaction assay, mycobacterial culture, or both. Humoral and cell-mediated immune responses were evaluated until month 36 in a subgroup of 300 participants. Safety was assessed in all participants who received at least one dose of M72/AS01E or placebo. RESULTS: A total of 3575 participants underwent randomization, of whom 3573 received at least one dose of M72/AS01E or placebo, and 3330 received both planned doses. Among the 3289 participants in the according-to-protocol efficacy cohort, 13 of the 1626 participants in the M72/AS01E group, as compared with 26 of the 1663 participants in the placebo group, had cases of tuberculosis that met the first case definition (incidence, 0.3 vs. 0.6 cases per 100 person-years). The vaccine efficacy at month 36 was 49.7% (90% confidence interval [CI], 12.1 to 71.2; 95% CI, 2.1 to 74.2). Among participants in the M72/AS01E group, the concentrations of M72-specific antibodies and the frequencies of M72-specific CD4+ T cells increased after the first dose and were sustained throughout the follow-up period. Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two groups. CONCLUSIONS: Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598. opens in new tab.)en_ZA
dc.description.sponsorshipGlaxoSmithKline Biologicals and Aerasen_ZA
dc.description.urihttps://www.nejm.org/doi/full/10.1056/NEJMoa1909953en_ZA
dc.description.versionPublisher’s versionen_ZA
dc.format.extent11 pagesen_ZA
dc.identifier.citationTait, Dereck R. et al. 2019. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 381(25):2429-2439. doi:10.1056/NEJMoa1909953en_ZA
dc.identifier.issn1533-4406 (online)en_ZA
dc.identifier.issn0028-4793 (print)en_ZA
dc.identifier.otherdoi:10.1056/NEJMoa1909953en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/123239en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherMassachusetts Medical Societyen_ZA
dc.rights.holderMassachusetts Medical Societyen_ZA
dc.subjectTuberculosis vaccinesen_ZA
dc.subjectTuberculosis -- Preventionen_ZA
dc.titleFinal analysis of a trial of M72/AS01E vaccine to prevent tuberculosisen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
tait_final_2019.pdf
Size:
397.64 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Infectious Diseases)